Call for Abstract/Travel Grant
Necessary information on an abstract
All abstracts shall be submitted through the online abstract submission system. Submitted abstracts shall be prepared according to the following instructions.
- Name of author
- Name of co-author(s)
- Institutional affiliation(s)
- Acceptance and the presentation style, Oral or Mini Oral, will be notified later.
- Please check the "Yes" if you are applying for a Travel Grant.
- Title of abstract – maximum of 100 characters
- Abstract – maximum of 1400 characters
- Charts and graphics cannot be registered.
※With the exception of advanced-level sessions (Presidential Sessions, Symposia, and Vid eo Symposia), duplicate presentations are not permitted; however, presentations based on data previo usly presented at international conferences are allowed, provided that this fact is clearly stated.
Disclosure of COI (Conflict of Interest)
All speakers are required to disclose any financial relationship (within the past 3 years) with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in subject matter or materials discussed in the abstract.
Category
＜Main Theme Session＞
The author who selected “Main Theme Session” can choose whether to apply for “General Session (Oral/Mini Oral)” if not accepted as Main Theme Session.
Presidential Selection
The role of sublobar resection for small-sized non-small cell lung cancer has evolved substantially following the results of the JCOG0802/WJOG4607L and CALGB140503 trials. For tumors with a solid-dominant appearance on imaging, segmentectomy offers the potential advantages of preserving pulmonary function while maintaining oncologic efficacy. However, concerns remain regarding local recurrence and optimal patient selection. This session will compare the outcomes of segmentectomy and lobectomy for solid-dominant small-sized lung cancer and discuss current evidence and future perspectives from the viewpoints of oncologic validity, postoperative function, and patient selection.
Advances in cancer treatment have prompted renewed discussion regarding the optimal primary endpoint for surgical oncology trials. Overall survival (OS) has traditionally been regarded as the gold standard because it directly reflects patient benefit. However, with the increasing impact of effective post-recurrence therapies, recurrence-free survival (RFS) has gained attention as a potentially more sensitive measure of the oncologic efficacy of surgical procedures. The JCOG0802/WJOG4607L trial highlighted this controversy by demonstrating improved OS despite a higher incidence of local recurrence in the segmentectomy arm, suggesting that OS and RFS may not always align. This session will explore the strengths and limitations of OS and RFS as primary endpoints in cancer surgery trials and discuss their implications for the design and interpretation of future surgical studies.
Symposium
Lung transplantation is an established final therapeutic option for patients with end-stage lung disease. However, transplant programs worldwide continue to face a major structural challenge: the persistent shortage of suitable donor organs. In recent years, advances such as ex vivo lung perfusion (EVLP) for the assessment and reconditioning of donor lungs, the expanded use of marginal donors and donation after circulatory death (DCD), and emerging technologies including xenotransplantation and regenerative medicine have begun to broaden the indications and possibilities of lung transplantation.
In Japan, the severe shortage of brain-dead donors has led living-donor lung transplantation to play an important role, while patients continue to face prolonged waiting times. As a result, lung transplantation in Japan has developed along a distinctive path, accumulating unique experience and expertise that differ from international trends.
In this session, we will compare the latest global developments in lung transplantation with the current situation, challenges, and unique strengths in Japan. We will also discuss the future direction of lung transplantation and the key issues that must be overcome.
In Japan, the severe shortage of brain-dead donors has led living-donor lung transplantation to play an important role, while patients continue to face prolonged waiting times. As a result, lung transplantation in Japan has developed along a distinctive path, accumulating unique experience and expertise that differ from international trends.
In this session, we will compare the latest global developments in lung transplantation with the current situation, challenges, and unique strengths in Japan. We will also discuss the future direction of lung transplantation and the key issues that must be overcome.
Advances in perioperative treatment, particularly the introduction of immune checkpoint inhibitors, have expanded the potential role of surgery in patients with locally advanced lung cancer. However, the definitions of “resectable” and “unresectable” disease remain controversial. In particular, treatment decision-making for patients with N2 disease or invasion of adjacent structures has become increasingly complex. This session will explore the assessment of resectability from both oncological and technical perspectives and discuss optimal treatment strategies and decision-making regarding surgical resection in patients with locally advanced lung cancer.
Segmentectomy has become established as a standard treatment for selected patients with small-sized peripheral non-small cell lung cancer (NSCLC) following the results of JCOG0802, as a surgical procedure that aims to achieve both preservation of pulmonary function and oncologic curability. More recently, clinical interest and research have increasingly expanded into areas for which supporting evidence remains insufficient, including larger tumors, centrally located tumors, cases with lymph node metastasis, and cases following neoadjuvant therapy.
In this session, we will examine, from anatomical, oncological, and technical perspectives, how far the indications for segmentectomy can be extended and at what point lobectomy should instead be selected. By bringing together the knowledge and experience of the speakers, we aim to discuss the validity and limitations of expanding the indications for segmentectomy, as well as the conditions required to ensure oncologic adequacy and surgical safety.
In this session, we will examine, from anatomical, oncological, and technical perspectives, how far the indications for segmentectomy can be extended and at what point lobectomy should instead be selected. By bringing together the knowledge and experience of the speakers, we aim to discuss the validity and limitations of expanding the indications for segmentectomy, as well as the conditions required to ensure oncologic adequacy and surgical safety.
The role of surgery in pleural mesothelioma has been called into question following the MARS 2 trial. In that study, the addition of extended pleurectomy/decortication (P/D) to chemotherapy did not provide a survival benefit and was associated with concerns regarding perioperative morbidity and quality of life. Nevertheless, advances in the new IASLC TNM classification, more refined patient selection, improvements in P/D techniques and perioperative management, and the development of multimodality treatment incorporating immunotherapy suggest that the role of surgery has not been completely eliminated.
This symposium will examine the interpretation of MARS 2, the new TNM classification, the indications and techniques for P/D, and perioperative systemic therapy. From both evidence-based and real-world perspectives, we will discuss whether surgery should be performed at all and, if so, in which patients and with which procedure, while exploring the current status and future direction of surgery for pleural mesothelioma.
This symposium will examine the interpretation of MARS 2, the new TNM classification, the indications and techniques for P/D, and perioperative systemic therapy. From both evidence-based and real-world perspectives, we will discuss whether surgery should be performed at all and, if so, in which patients and with which procedure, while exploring the current status and future direction of surgery for pleural mesothelioma.
In the field of thoracic surgery, the spread of minimally invasive surgery and immunotherapy has positioned surgical treatment at the core of multimodal therapy, highlighting the importance of generating clinical evidence led by surgeons. In Japan, high-quality clinical trials have been conducted mainly by organizations such as the JCOG, WJOG, and NEJ, based on precise surgical techniques and the accumulation of follow-up data. Recently, these have received high international acclaim, particularly in the field of limited resection. However, challenges remain that limit the dissemination of Japan-originated evidence, such as the uneven distribution of cases, insufficient research support systems, and issues related to participation in international collaborative research. We would like you to review the current state of clinical trials in thoracic surgery, clarify both strengths and challenges, and discuss future directions for research infrastructure.
In recent years, thoracic surgery has witnessed remarkable technological innovations, including robot-assisted surgery, navigation technology, and molecular imaging. Advanced navigation systems that combine preoperative imaging with robot-assisted surgery using AI and systems that support surgeons’ decision-making by performing real-time AI analysis of intraoperative camera images to visualize dissection planes and critical structures have also been introduced. We would like you to discuss the current status of cutting-edge technologies in the field of thoracic surgery, and future directions and possibilities.
The five-year survival rate after brain-dead and living-donor lung transplantation in Japan is approximately 73%, which greatly exceeds the international registry’s rate of approximately 55% for brain-dead lung transplants. However, further improvements in survival rates, addressing donor shortages, and overcoming chronic rejection remain major challenges. In recent years, innovative approaches, such as ex vivo lung perfusion (EVLP) for donor lung assessment and repair, mitigation of ischemia–reperfusion injury, and research on early diagnostic biomarkers for chronic rejection, have been reported. Additionally, with the launch of the comprehensive organ transplant registry (TRACER), not only the visibility of complications and prognostic outcomes but also the development of AI-based prognostic prediction models is anticipated. We would like you to discuss the current status and challenges of lung transplantation, the latest technological innovations, and future prospects of the field.
Video Symposium
Achieving both oncologic efficacy and minimal invasiveness remains a central goal in lung cancer surgery. Robotic-assisted thoracic surgery has rapidly expanded in recent years, driven by enhanced dexterity, articulated instrumentation, and high-definition three-dimensional visualization. Its application now extends beyond standard lobectomy to complex segmentectomy and advanced thoracic procedures. Nevertheless, important questions remain regarding long-term oncologic outcomes, cost-effectiveness, surgical training and credentialing, and integration with emerging technologies such as artificial intelligence and image-guided navigation. This session will review the evolution of robotic surgery in lung cancer treatment, highlight the latest evidence and technological advances, and discuss future directions for thoracic surgical oncology.
While lobectomy remains the standard surgical procedure for lung cancer, reconstructive techniques such as bronchoplasty and pulmonary artery angioplasty play a pivotal role in the management of centrally located and locally advanced tumors. These procedures enable parenchymal preservation without compromising oncologic principles, thereby contributing to improved postoperative function and quality of life. However, successful implementation requires meticulous preoperative planning, advanced technical expertise, and careful patient selection. In this video symposium, expert thoracic surgeons will demonstrate complex reconstructive procedures and share technical insights, strategies for ensuring safety, and the oncologic and functional benefits that define the true value of reconstructive thoracic surgery.
As thoracic surgery becomes increasingly minimally invasive, major vascular injury remains one of the most serious intraoperative complications, requiring prompt and appropriate management. In addition, advances in perioperative treatment have increased operative complexity. This video symposium will present cases of major intrathoracic vascular bleeding and discuss strategies for initial management, exposure, hemostasis, conversion to thoracotomy, and team communication to improve surgical safety.
Lung transplantation is an important treatment option for patients with end-stage respiratory failure, requiring advanced surgical skills and flexible decision-making to address the diverse clinical backgrounds of recipients. In addition to selecting appropriate surgical strategies, prompt and effective management of unexpected complications is essential. This video symposium will present real-world cases to share technical tips, intraoperative decision-making, and strategies for managing perioperative challenges. Through discussion of practical experiences, we aim to improve the safety and quality of lung transplantation.
＜General Session (Oral/ Mini Oral)＞
| 01 | Lung Cancer - Extended Surgery | 20 | Congenital and Pediatric Respiratory Diseases |
|---|---|---|---|
| 02 | Lung Cancer - Limited Resection | 21 | Lung Transplantation - Clinical |
| 03 | Lung Cancer - Basic Research (Pathology, Immunology, Genomics) | 22 | Lung Transplantation - Basic Research |
| 04 | Lung Cancer - Perioperative Treatment | 23 | Regenerative Medicine |
| 05 | Lung Cancer with Comorbidities | 24 | Advanced Therapies and Image-Guided Surgery |
| 06 | Lung Cancer - Multimodal Treatment | 25 | Artificial Intelligence (AI) |
| 07 | Lung Cancer - Miscellaneous | 26 | Uniportal VATS |
| 08 | Benign Lung Tumors | 27 | Robotic-Assisted Thoracic Surgery (RATS) |
| 09 | Pulmonary Metastases | 28 | Troubleshooting in Thoracic Surgery |
| 10 | Mediastinal Tumors | 29 | Perioperative Management and Postoperative Complications |
| 11 | Thymoma, Thymic Carcinoma, Myasthenia Gravis | 30 | Pulmonary Rehabilitation |
| 12 | Other Mediastinal Diseases | 31 | Basic Research |
| 13 | Cystic Lung Disease, Pneumothorax | 32 | Translational Research |
| 14 | Infectious Pulmonary Diseases, Empyema | 33 | Health Economics |
| 15 | Tracheal and Bronchial Diseases | 34 | Clinical Trials |
| 16 | Airway Interventions | 35 | Education |
| 17 | Mesothelioma, Pleural Diseases | 36 | Patient Safety |
| 18 | Diseases of the Chest Wall, Thoracic Cage, and Diaphragm | 37 | Miscellaneous |
| 19 | Thoracic Trauma | ||
Travel Grant
The organizing committee of the 44th Annual Meeting of the Japanese Society of Thoracic Surgeons (JSTS) encourages young surgeons from overseas to submit original abstracts for Oral or Mini Oral. Those who submit an abstract can apply for a travel grant.
- Applicants should be at the age of 45 or younger.
- Foreign nationalities residing in Japan are not eligible for this grant.
- A maximum of 10 recipients will be awarded 50,000JPY in appreciation of the presentation by the 44th Annual Meeting of the Japanese Society of Thoracic Surgeons.
- The organizing committee is unable to cover the cost of registration/accommodation expenses.
- It is the applicants' responsibility to obtain the necessary visa for entering Japan prior to the congress.
- Grant recipients will receive notification at the beginning of March, 2027.
Application deadline
Noon, Tuesday, December 1, 2026 (JST)
Abstract Submission
All abstracts shall be submitted through the online abstract submission system.
New SubmissionConfirmation / Modify
Contact Us
Congress Secretariat
c/o Next Innovation Partners Inc.
E-mail：jacs2027@nip-sec.com